BTIG Maintains a Hold Rating on Viewray (VRAY)

By Ryan Adsit

In a report released yesterday, Marie Thibault from BTIG maintained a Hold rating on Viewray (VRAYResearch Report). The company’s shares closed last Thursday at $2.08, close to its 52-week low of $1.11.

According to, Thibault is a 3-star analyst with an average return of 8.8% and a 52.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Edwards Lifesciences.

Viewray has an analyst consensus of Hold, with a price target consensus of $3.00, implying a 53.8% upside from current levels. In a report issued on April 28, Guggenheim also downgraded the stock to Hold.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.77 and a one-year low of $1.11. Currently, Viewray has an average volume of 2.07M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.